Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.07
AMRI's Cash-to-Debt is ranked lower than
97% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. AMRI: 0.07 )
Ranked among companies with meaningful Cash-to-Debt only.
AMRI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 4.57 Max: No Debt
Current: 0.07
Equity-to-Asset 0.26
AMRI's Equity-to-Asset is ranked lower than
86% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AMRI: 0.26 )
Ranked among companies with meaningful Equity-to-Asset only.
AMRI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.8 Max: 0.96
Current: 0.26
0.25
0.96
Debt-to-Equity 2.04
AMRI's Debt-to-Equity is ranked lower than
92% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. AMRI: 2.04 )
Ranked among companies with meaningful Debt-to-Equity only.
AMRI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.05 Max: 2.16
Current: 2.04
0
2.16
Debt-to-EBITDA 11.86
AMRI's Debt-to-EBITDA is ranked lower than
93% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. AMRI: 11.86 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AMRI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.72  Med: 0.44 Max: 20.13
Current: 11.86
-2.72
20.13
Piotroski F-Score: 4
Altman Z-Score: 0.91
Beneish M-Score: -2.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -3.02
AMRI's Operating Margin % is ranked higher than
70% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. AMRI: -3.02 )
Ranked among companies with meaningful Operating Margin % only.
AMRI' s Operating Margin % Range Over the Past 10 Years
Min: -36.35  Med: 1.19 Max: 11.32
Current: -3.02
-36.35
11.32
Net Margin % -8.78
AMRI's Net Margin % is ranked higher than
67% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. AMRI: -8.78 )
Ranked among companies with meaningful Net Margin % only.
AMRI' s Net Margin % Range Over the Past 10 Years
Min: -31.74  Med: -1.54 Max: 8.97
Current: -8.78
-31.74
8.97
ROE % -19.74
AMRI's ROE % is ranked higher than
63% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. AMRI: -19.74 )
Ranked among companies with meaningful ROE % only.
AMRI' s ROE % Range Over the Past 10 Years
Min: -23.94  Med: -1.72 Max: 6.22
Current: -19.74
-23.94
6.22
ROA % -5.26
AMRI's ROA % is ranked higher than
72% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. AMRI: -5.26 )
Ranked among companies with meaningful ROA % only.
AMRI' s ROA % Range Over the Past 10 Years
Min: -17.99  Med: -1.15 Max: 5.29
Current: -5.26
-17.99
5.29
ROC (Joel Greenblatt) % -2.60
AMRI's ROC (Joel Greenblatt) % is ranked higher than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. AMRI: -2.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMRI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -35.54  Med: 1.48 Max: 13.51
Current: -2.6
-35.54
13.51
3-Year Revenue Growth Rate 24.40
AMRI's 3-Year Revenue Growth Rate is ranked higher than
77% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AMRI: 24.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMRI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 8.5 Max: 78
Current: 24.4
-1.6
78
3-Year EBITDA Growth Rate -10.40
AMRI's 3-Year EBITDA Growth Rate is ranked lower than
65% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. AMRI: -10.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMRI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -48.6  Med: 9.55 Max: 60.9
Current: -10.4
-48.6
60.9
GuruFocus has detected 6 Warning Signs with Albany Molecular Research Inc AMRI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMRI's 30-Y Financials

Financials (Next Earnings Date: 2018-02-21 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

AMRI Guru Trades in Q4 2016

Jim Simons 357,900 sh (+3.07%)
Chuck Royce 1,290,911 sh (+2.92%)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 80,589 sh (-48.93%)
» More
Q1 2017

AMRI Guru Trades in Q1 2017

Paul Tudor Jones 16,300 sh (New)
Ken Fisher 144,417 sh (+79.20%)
Chuck Royce 1,518,276 sh (+17.61%)
Murray Stahl 56,000 sh (unchged)
Jim Simons 148,342 sh (-58.55%)
» More
Q2 2017

AMRI Guru Trades in Q2 2017

Mario Gabelli 162,073 sh (New)
John Paulson 314,200 sh (New)
Jim Simons 295,542 sh (+99.23%)
Ken Fisher 184,589 sh (+27.82%)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 396,275 sh (-73.90%)
» More
Q3 2017

AMRI Guru Trades in Q3 2017

Mario Gabelli Sold Out
John Paulson Sold Out
Murray Stahl Sold Out
Jim Simons Sold Out
Chuck Royce Sold Out
Ken Fisher Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-09-30 Sold Out 0.01%$21.62 - $21.76 $ 21.740%0
Mario Gabelli 2017-09-30 Sold Out 0.02%$21.62 - $21.76 $ 21.740%0
John Paulson 2017-09-30 Sold Out 0.09%$21.62 - $21.76 $ 21.740%0
John Paulson 2017-06-30 New Buy0.09%$13.37 - $21.72 $ 21.7420%314,200
Ken Fisher 2017-06-30 Add 27.82%$13.37 - $21.72 $ 21.7421%184,589
Mario Gabelli 2017-06-30 New Buy0.02%$13.37 - $21.72 $ 21.7421%162,073
Ken Fisher 2017-03-31 Add 79.20%$13.06 - $19.29 $ 21.7433%144,417
Ken Fisher 2016-12-31 Reduce -48.93%$14.57 - $18.84 $ 21.7428%80,589
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:NAS:XNCR, ROCO:4174, NAS:EDIT, XMCE:ROVI, SZSE:002604, SZSE:300149, NAS:ENTA, OSTO:HMED, SZSE:300363, SAU:2070, NAS:ATNX, NAS:AMRN, XSWX:BSLN, NAS:RGNX, NAS:NTLA, TSX:PLI, SZSE:300381, XSWX:HBMN, SZSE:300147, NAS:RXDX » details
Traded in other countries:AYM.Germany,
Headquarter Location:USA
Albany Molecular Research Inc is a contract research and manufacturing company, providing customers drug discovery, development and manufacturing services.

Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.

Top Ranked Articles about Albany Molecular Research Inc

3ST Research Files Litigation Alleging Fraud and Conversion of Inventor's Intellectual Property Rights by Albany Molecular Research Inc. (AMRI)
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR
Control4 Set to Join S&P SmallCap 600
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Albany Molecular Research, Inc. – AMRI
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. (AMRI)
WeissLaw LLP: The Proposed Acquisition of Albany Molecular Research Inc. May Not Be In the Best Interest of AMRI Shareholders
Harwood Feffer LLP Announces Investigation of Albany Molecular Research, Inc.
ALBANY MOLECULAR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albany Molecular Research, Inc.
Albany Molecular (AMRI) Alert: J&W Investigates Price and Process of Proposed Sale of Albany Molecular Research, Inc.; Is $21.75 a Fair Price?
AMRI Signs Definitive Agreement To Be Acquired By The Carlyle Group and GTCR for $21.75 per share in cash

Ratios

vs
industry
vs
history
Forward PE Ratio 19.42
AMRI's Forward PE Ratio is ranked higher than
62% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. AMRI: 19.42 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.95
AMRI's PB Ratio is ranked higher than
64% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AMRI: 2.95 )
Ranked among companies with meaningful PB Ratio only.
AMRI' s PB Ratio Range Over the Past 10 Years
Min: 0.29  Med: 1.34 Max: 3.09
Current: 2.95
0.29
3.09
PS Ratio 1.35
AMRI's PS Ratio is ranked higher than
92% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. AMRI: 1.35 )
Ranked among companies with meaningful PS Ratio only.
AMRI' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 1.34 Max: 2.93
Current: 1.35
0.31
2.93
Price-to-Operating-Cash-Flow 46.85
AMRI's Price-to-Operating-Cash-Flow is ranked lower than
72% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. AMRI: 46.85 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMRI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.92  Med: 16.17 Max: 314.81
Current: 46.85
4.92
314.81
EV-to-EBIT -111.07
AMRI's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. AMRI: -111.07 )
Ranked among companies with meaningful EV-to-EBIT only.
AMRI' s EV-to-EBIT Range Over the Past 10 Years
Min: -239  Med: 17.8 Max: 455
Current: -111.07
-239
455
EV-to-EBITDA 28.24
AMRI's EV-to-EBITDA is ranked lower than
62% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. AMRI: 28.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMRI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -40.2  Med: 9.9 Max: 43.6
Current: 28.24
-40.2
43.6
EV-to-Revenue 2.27
AMRI's EV-to-Revenue is ranked higher than
87% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. AMRI: 2.27 )
Ranked among companies with meaningful EV-to-Revenue only.
AMRI' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.3  Med: 1.4 Max: 3.3
Current: 2.27
0.3
3.3
Current Ratio 0.68
AMRI's Current Ratio is ranked lower than
92% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. AMRI: 0.68 )
Ranked among companies with meaningful Current Ratio only.
AMRI' s Current Ratio Range Over the Past 10 Years
Min: 0.68  Med: 5.35 Max: 17.83
Current: 0.68
0.68
17.83
Quick Ratio 0.37
AMRI's Quick Ratio is ranked lower than
94% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. AMRI: 0.37 )
Ranked among companies with meaningful Quick Ratio only.
AMRI' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 4.51 Max: 17.25
Current: 0.37
0.37
17.25
Days Inventory 113.19
AMRI's Days Inventory is ranked higher than
58% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. AMRI: 113.19 )
Ranked among companies with meaningful Days Inventory only.
AMRI' s Days Inventory Range Over the Past 10 Years
Min: 57.53  Med: 63.97 Max: 113.19
Current: 113.19
57.53
113.19
Days Sales Outstanding 74.70
AMRI's Days Sales Outstanding is ranked lower than
56% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. AMRI: 74.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.89  Med: 64.89 Max: 100.17
Current: 74.7
43.89
100.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.70
AMRI's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. AMRI: -10.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMRI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.7  Med: -0.6 Max: 2.8
Current: -10.7
-10.7
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.91
AMRI's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
53% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. AMRI: 3.91 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMRI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.4  Med: 0.9 Max: 3.91
Current: 3.91
0.4
3.91
Price-to-Median-PS-Value 1.00
AMRI's Price-to-Median-PS-Value is ranked lower than
52% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. AMRI: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMRI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.41 Max: 38.75
Current: 1
0.28
38.75
Price-to-Peter-Lynch-Fair-Value 7.91
AMRI's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. AMRI: 7.91 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AMRI' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 2.08 Max: 80.81
Current: 7.91
0
80.81
Earnings Yield (Greenblatt) % -0.90
AMRI's Earnings Yield (Greenblatt) % is ranked higher than
72% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. AMRI: -0.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMRI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -107.7  Med: 1.2 Max: 16.5
Current: -0.9
-107.7
16.5
Forward Rate of Return (Yacktman) % 17.03
AMRI's Forward Rate of Return (Yacktman) % is ranked higher than
58% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 13.13 vs. AMRI: 17.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AMRI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -16.6  Med: 0.8 Max: 21.2
Current: 17.03
-16.6
21.2

More Statistics

Revenue (TTM) (Mil) $680.81
EPS (TTM) $ -1.41
Short Percentage of Float21.10%
52-Week Range $13.01 - 22.17
Shares Outstanding (Mil)43.12

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 722 780
EPS ($) 1.12 1.50
EPS without NRI ($) 1.12 1.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}